Esperion announces public offering of common stock

Esperion Therapeutics Inc. (NASDAQ: ESPR) announced it has commenced an underwritten public offering of common stock shares. The biopharmaceutical company also plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered in the public offering.

All shares in the proposed offering will be sold by Esperion. The company stated the offering is subject to market and other conditions, with no assurance regarding completion timing or final terms.

Piper Sandler & Co. and Cantor Fitzgerald & Co. are serving as joint book-running managers for the proposed offering.

The shares are being offered under an effective shelf registration statement filed with the Securities and Exchange Commission on April 18, 2025, and declared effective on April 29, 2025. A preliminary prospectus supplement describing the offering terms will be filed with the SEC.

Esperion develops and commercializes oral, once-daily, non-statin medicines for patients with elevated low-density lipoprotein cholesterol. The company's medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients.

The company is also developing ATP citrate lyase inhibitors as part of its next generation program and continues to advance its pre-clinical pipeline through commercial execution and international partnerships.

You May Also Be Interested In

• Gossamer Bio raises up to $250M in private placement for PAH drug
• Elroy Air wins $46M U.S. Army contract for cargo drone system
• Aveanna selling stockholders launch 15M share secondary offering